Kornimate/medical-research-clean huggingface dataset:
arthritis health journal proof of concept study

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine whether an online patient passport tool called the arthritis health journal can assist people with rheumatoid arthritis in managing their disease.

patient passports have been developed and used in chronic diseases, such as diabetes, to promote active involvement of patients in their care, and have led to better treatment and health outcomes. in rheumatoid arthritis (ra), active involvement of patients in monitoring their symptoms and their disease activity may facilitate treatment according to current recommendations, which emphasize the need for aggressive treatment to suppress inflammation and for using a "treat to target" approach where treatment is escalated until a target is reached and is promptly modified when target is no longer met. in this study, the investigators have developed an online tool that aims to help people with ra monitor their symptoms and their disease activity and self-manage their arthritis. the investigators will perform a proof of concept study assessing how the arthritis health journal affects consumer effectiveness, patient self-efficacy, communication with health professionals, shared decision-making, and satisfaction with medical care. the investigators will also evaluate the feasibility and satisfaction with using the arthritis health journal. the investigators will use a stepped wedge study design, in which 50 participants will be randomized to either the intervention group (immediate use of the arthritis health journal) or the control group (waitlisted for 6 months). due to the nature of the intervention, the study is not blinded.

Eligibility criteria:
inclusion criteria: * be 18 years of age or older * have a diagnosis of rheumatoid arthritis * be under the ongoing care of a rheumatologist * be comfortable using a computer and online applications * have access to an internet connection * be able to read and write english without needing a translator exclusion criteria: * younger than 18 years of age; * diagnoses of arthritis other than rheumatoid arthritis * not under the ongoing care of a rheumatologist * not comfortable using a computer * lack of internet access * inability to read and write in english without a translator

Keywords: rheumatoid arthritis self-management online patient passport
optimal application dose of superficial hyperthermia

Conditions: Tumors

Summary: hyperthermia - a warming of the tumor at 42-43 ° c - in combination with radiation and / or chemotherapy is a proven method of treatment for malignant tumors. the amplification of the effect of radiotherapy and various chemotherapeutic agents (platinum analogues, nitrogen-lost derivatives, cytotoxic antibiotics) is experimentally demonstrated. randomized clinical trials have shown a better chance of survival and better local tumor control without increasing the toxicity of combined treatment especially also in children's tumors. the combination of hyperthermia and radiation therapy is more effective than radiotherapy alone. hyperthermal temperatures increase blood circulation in tumors as a response to stimulation with heat. tumor tissue, having a minor circulation and being acidotic, is resistant to radiotherapy, but sensitive to hyperthermia, while tumor with a high blood flow is sensitivity to radiation. this positive interaction is a compelling reason for the combination of hyperthermia and ionized radiation. hyperthermia, in combination with chemotherapy, increases the concentration of cytostatics in the tumor region, raising blood flow caused by warmth. in addition, hyperthermia increases toxicity of drugs in cells, being normally resistant to many drugs. hyperthermia can synergistically be combined with chemotherapy treating "high risk" - tumors with curative intention. in addition to the clinical use of surface hyperthermia (bsd 500 - o), with appropriate treatment of tumors up to 3 cm deep from the surface of the body with established indications and palliative indication in advanced stages of cancer, a prospective, randomized study with quality-controlled thermometry shall establish the optimal sequence of hyperthermia in combination with irradiation. therefore the treatment sequence of once per weeks is compared to a sequence of three times per week.


Eligibility criteria:
inclusion criteria: * surficial tumors (\< 3-4 cm) * ≥ 18 years * karnofsky index \> 60 * no other treatment in between 30 d, applicable radiation dose min.30 gy * cumulative equivalent minutes 42°c t75 exclusion criteria: * pregnancy * pace maker * metal implants

Keywords: hyperthermia superficial tumor treatment superficial tumors
a combined biomarker model for risk stratification of indeterminate pulmonary nodules

Conditions: Pulmonary Nodule

Summary: this is a prospective, multicenter observational study aim at estimating the potential clinical utility of the cbm and at establishing the sops and protocols for a future randomized control trial.

objectives: * to obtain the combined biomarker model (hs-cyfra 21-1, radiomics, mayo) score in a prospective observational trial and estimate potential clinical utility compared to the mayo model. * to establish standard operating procedures (sops) and protocols in a prospective observational trial in anticipation of a future randomized control trial. these include the redcap data input protocols, the radiomic protocols, blood draws in the clia environment, and estimating the cbm score in a time reasonable for clinical practice (\< 2 weeks).

Eligibility criteria:
inclusion criteria: * adults \> 21 y/o * ipns 8-30mm referred for evaluation figure 4. auc and reclassification of combined biomarker model * intermediate risk ipn defined as 10-70% risk after applying mayo risk predictor model * solid nodules or part-solid nodules with solid component \>=8mm * ct scan with nodule of concern performed within 60 days of enrollment exclusion criteria: pure ground glass nodule or subsolid nodule with solid component \<8mm * currently on therapy for any cancer * history of primary lung cancer within the last 5 years * multiple nodules highly suspicious for metastatic disease * other malignancy within the last 2 year - excluding skin cancer other than melanoma * pregnant women * prisoners * inability to provide informed consent * serologic evidence of active fungal infection
a study to assess the efficacy and safety of asp1941 in combination with metformin in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: this study is to evaluate the efficacy and safety after concomitant administration of asp1941 and metformin in patients with diabetes mellitus.

this study is to evaluate the efficacy (hba1c change from baseline) and safety of asp1941 in combination with metformin in subjects with type 2 diabetes mellitus (t2dm) who have inadequate glycemic control with metformin alone. the effects of asp1941 are compared with those of placebo.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients receiving with metformin mono-therapy for at least 6 weeks * hba1c value between 7.0 and 9.5% * body mass index (bmi) 20.0 - 45.0 kg/m2 exclusion criteria: * type 1 diabetes mellitus patients * serum creatinine \> upper limit of normal * estimated gfr \< 60ml/min/1.73m2 * proteinuria (albumin/creatinine ratio \> 300mg/g) * dysuria and/or urinary tract infection, genital infection * significant renal, hepatic or cardiovascular diseases * severe gastrointestinal diseases

Keywords: diabetes mellitus metformin asp1941
a study on emergence of resistance with oseltamivir (tamiflu) in participants with seasonal influenza

Conditions: Influenza

Summary: this open-label randomized 2 arm study will determine the emergence of viral resistance in participants with seasonal influenza a infection treated with oseltamivir. eligible participants less than or equal to (\ ) 100.


Eligibility criteria:
inclusion criteria: * positive rapid antigen test for influenza a * onset of symptoms of influenza (fever, at least one respiratory symptom) \</=48 hours exclusion criteria: * clinical suspicion of infection with a respiratory virus other than influenza * suspicion of invasive bacterial infection * evidence of poorly controlled underlying disease * known immunosuppression * known allergy to oseltamivir * women who are pregnant or planning to get pregnant during the study
collection of additional biological samples from potentially covid-19 patients for monitoring of biological parameters carried out as part of the routine

Conditions: SARS CoV 2 Infection

Summary: patients infected with sars-cov-2 can present with a wide range of manifestations clinical conditions, ranging from no symptoms to serious or chronic illness. the current gold standard test for the diagnosis of covid-19 is based on a molecular test of reverse transcription polymerase chain reaction (rt-pcr), aimed at detecting the rna of the virus in respiratory samples such as nasopharyngeal swabs or aspirates bronchial, other methods such as antigen tests and serological detection tests igm and igg in response to covid-19 viral infection, can be used for the purposes of screening in the general population. in this context of variety of existing tests, it is important to monitor the biological parameters related to covid-19 pathology by tracking the accuracy, specificity and sensitivity of these tests in current clinical practice. this research is a collection of additional biological samples with minimal impact on the intake usual care of the patients concerned, for the monitoring of biological parameters carried out in routine on several reagent kits used for screening for the sars-cov-2 virus, in terms of sensitivity, specificity, positive and negative predictive values, for the implementation of indicators quality monitoring of these kits.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * patient coming for a biological analysis as part of the care for prevention, screening or monitoring of the pathogen target * patient able to understand the information note and give a free and informed consent, on paper or digital media * clinical patients: * control cases (all comers or ambulatory) * known positive for the pathology concerned * patient hospitalized for the pathology concerned * pregnant or breastfeeding patient * dialysis patient exclusion criteria: * patient already included in a research protocol * patient having received medication or treatment experimental or investigational during the last four weeks before collection * patient subject to a legal protection measure * patient affiliated with state medical aid (ame) * patient not affiliated to the compulsory social security system * refusal or inability to provide signed informed consent * according to the investigator, the patient is not eligible for inclusion in the study
functional training for the prevention of deep venous thrombosis

Conditions: Ankle Motion; Gynecologic Neoplasm; Deep Venous Thrombosis; Abdominal Breathing

Summary: this study aims to analyze the post-operative functional training on the prevention of deep venous thrombosis (dvt) in the patients who have accepted major surgeries for the gynecological malignancies. the functional training consists of: (1) active and passive ankle pump motions including flexion and extension, circumduction; (2) abdominal breathing training. the primary end is the incidence of dvt happened 30 days from surgery. the secondary ends include the patients satisfaction about functional training.


Eligibility criteria:
inclusion criteria: * having received major surgeries for gynecologic malignancies * good performance status * aged 18 years or older * signed an approved informed consents * no injuries to the skin, musculoskeletal system * no venous thromboembolic disease before surgeries exclusion criteria: * not meeting all of the inclusion criteria * delayed extubation
study of rifaximin in minimal hepatic encephalopathy

Conditions: Minimal Hepatic Encephalopathy

Summary: rifaximin therapy will improve brain functioning on mri scanning and change the microbiome and metabolome.


Eligibility criteria:
inclusion criteria: * age 18-65 years * cirrhosis diagnosed by clinical or biopsy grounds * minimal hepatic encephalopathy defined by impaired performance on at least 2 of the following: number connection tests a/b, digit symbol and block design tests (nct-a, nct-b, dst and bdt) compared to age and education-matched controls. * no contraindications to mri * tips (transjugular intra-hepatic porto-systemic shunt) procedure or elective surgery planned within the next 8 weeks exclusion criteria: * current therapy with lactulose, rifaximin or other treatment for hepatic encephalopathy. * prior episodes of overt he * mmse \<25 * tips placement * unable to give informed consent. * contra-indications to mri

Keywords: minimal hepatic encephalopathy cirrhosis complications
a health economic trial in adult patients undergoing open colectomy ma402s23b302

Conditions: Bowel Obstruction

Summary: this study is designed to compare the standard of care against exparel (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using exparel, therefore possibly reducing total hospitalization costs.

this is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with exparel (bupivacaine liposome extended-release injectable suspension), compared with postsurgical administration of standardized intravenous (iv) morphine sulfate, for postsurgical analgesia in adult patients undergoing open colectomy with general anesthesia.

Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or older. * patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy. * ability to provide informed consent, adhere to study visit schedule, and complete all assessments. exclusion criteria: * patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol. * patients who abuse alcohol or other drug substance. * patients with severe hepatic impairment. * patients currently pregnant or who may become pregnant during the course of the study. * patients with any psychiatric, psychological, or other condition that the investigator feels may make the patient an inappropriate candidate for this clinical study. * patients who have participated in a exparel study within the last 30 days. * patients who have received an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study. * patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery. in addition, the patient will be ineligible if he/she meets the following criteria during surgery: * patients with unplanned multiple segmental resections or large intestine. * patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed. * patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or an other analgesic, local anesthetics, or anti-inflammatory agents. * patients who receive entereg(r).

Keywords: open colectomy colectomy
mesotherapy versus systemic therapy in treating neck pain related to herniated disc

Conditions: Emergencies

Summary: introduction: neck pain is a global public health concern, that ranked 4th highest health condition in terms of disability as measured by years lived with disability. the aim of this study is to compare the efficiency of one-session mesotherapy application with systemic therapy in treating neck pain related to cervical disk herniation. methods: this is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with neck pain related to cervical disc herniation. a mixture of thiocolchicoside, lidocaine and tenoxicamwas administered via mesotherapy in one group, and intravenous administration of dexketoprofen was applied to the other group. we compared the changes in pain intensity at 60thminute, 120thminute and 24th hours after treatment using visual analogue scale (vas),and adverse effects of the treatment methods among the study groups.


Eligibility criteria:
inclusion criteria: * 18 years and older age * admission to emergency department (ed) with acute cervical pain related to cervical disk herniation. exclusion criteria: * taking analgesic drugs before admission * having vas score of lower than 4 on admission * having diabetes mellitus * body mass index\>30 kg/m2 * pregnancy * lactation * having active bleeding or bleeding disorder * having active or recurrent gastrointestinal hemorrhage or ulcer, or history of these conditions * having a serious or life-threatening condition (stroke, intracranial hemorrhage, heart attack, cardiac tamponade, pneumothorax, hemothorax, flail chest, etc.).

Keywords: mesotherapy neck pain
extension study to provide continued treatment for patients with hematologic malignancies previously enrolled in studies with tafasitamab

Conditions: Hematologic Malignancies

Summary: this extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..


Eligibility criteria:
inclusion criteria: * capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol. * having been enrolled and is still receiving treatment with tafasitamab at the end of a parent tafasitamab clinical study. * is tolerating tafasitamab treatment at the dose specified in the parent protocol as assessed by the investigator. * is in complete/partial response or stable disease and is receiving clinical benefit from treatment with tafasitamab in the parent study, as assessed by the investigator. * has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements. * willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol. exclusion criteria: * patient who is legally institutionalized, or under judicial protection. * has met one or more criteria for permanent tafasitamab treatment discontinuation as stipulated in the parent protocol. * able to access tafasitamab outside a clinical study. * patient with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol. * a female patient who is pregnant confirmed by a pregnancy test prior to enrollment, breastfeeding, or a woman of childbearing potential (wocbp) who does not agree to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of study treatment, and does not refrain from donating oocytes during this period. * a male patient who does not agree to use contraception as detailed in the contraceptive guidance during the treatment period and for at least 3 months after the last dose of study treatment (if they have a heterosexual partner who is a woman of childbearing potential) and who does not refrain from donating sperm during this period.
bosutinib treatment extension study only for subjects with chronic myeloid leukemia (cml) who have previously participated in bosutinib studies b1871006 or b1871008

Conditions: Chronic Myeloid Leukemia

Summary: the objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.


Eligibility criteria:
inclusion criteria: * only subjects previously participating in two specific studies are eligible to enroll into this study. enrollment is not open to subjects if not previously enrolled in studies b1871006 or b1871008. exclusion criteria: * all subjects are excluded unless previously participating in studies b1871006 or b1871008.

Keywords: subjects chronic myeloid leukemia cml bosutinib extension
research and development of a new technology for detection of abnormal excretion of intestinal uric acid involved in the incidence of gout

Conditions: Gout; Hyperuricemia; Gut Microbiota; Uric Acid; Genetic Loci; Single Nucleotide Polymorphism; Feces

Summary: to evaluate differences in specific snps and intestinal microflora between patients with gout and hyperuricemia and healthy controls.

1. to evaluate differences in specific snps and intestinal microflora between patients with gout and hyperuricemia and healthy controls. 2. to measure the level of uric acid in feces.

Eligibility criteria:
gout inclusion criteria: 1. age:year of 25\~60; 2. be consistent with the 2015 american college of rheumatology/ european league against rheumatism (acr/eular) gout diagnostic criteria ,and serum uric acid \>420 μmol/l; 3. the patient are willing to take part in our study. exclusion criteria: 1. abronia, surgery, postoperative, dehydration within 2 weeks, acute or chronic infectious diseases, severe trauma, malnutrition, diabetes, malignant tumors; 2. diagnosed as cardiovascular and cerebrovascular diseases within 3 months; 3. heart failure (new york heart academy，grade iv); 4. hepatic insufficiency ( alanine transaminase or aspartate aminotransferase ≥3×upper limit)； 5. chronic kidney disease or abnormal renal function( serum creatinine ≥1.5×upper limit)； 6. excessive drinking； 7. the investigators considered the patients unsuitable for inclusion in this study. hyperuricemia: inclusion criteria: 1. age:year of 25\~60; 2. a medical record in our hospital showed that the person is healthy, without key disease; 3. serum uric acid \>420μmol/l without gout flares. exclusion criteria:same as the group of gout. healthy controls: inclusion criteria: age:year of 25\~60; a medical record in our hospital showed that the person is healthy, without key disease; serum uric acid ≤420μmol/l. exclusion criteria:same as the group of gout.